

PRESS RELEASE

CORPORATE MEDIA RELATIONS

Supervisory Board changes announced

Arnhem, the Netherlands, October 17, 2005 - Following a long and distinguished career, former CEO of Akzo Nobel Aarnout Loudon has announced that he will not be eligible for re-appointment as a member of the Company's Supervisory Board as of May 1, 2006, when his current term ends. He will be succeeded as Chairman of the Supervisory Board by the current Deputy Chairman, Maarten van den Bergh.

First employed by Akzo NV in 1969, **Mr. Loudon** became Chairman of the Board of Management in 1982, a position he held for 12 years until his retirement in 1994. He has been Chairman of the Supervisory Board of Akzo Nobel NV since 1995.

CEO during some of the most significant developments in the Company's recent history, he guided Akzo through its merger with Nobel and laid the foundations for the significant growth which followed.

"I would like to extend the appreciation of the whole Board of Management to Mr Loudon for all his sterling efforts during his highly successful 36 years with us," said CEO Hans Wijers. "He helped mould Akzo Nobel into the global force that it is today and should be very proud of the pivotal role he has played in the Company's success."

Mr Loudon's successor, **Maarten van den Bergh**, is Chairman of Lloyds TSB Group and a non-executive director of Royal Dutch Shell plc. Born in New York in 1942 but now resident in the UK, he is also a non-executive board member of British Airways plc and British Telecom plc. He joined Akzo Nobel's Supervisory Board in 2005.

It has also been announced that after a combined term of nine years, **Lars Thunell** will step down from his position as a member of Akzo Nobel's Supervisory Board as of December 31, 2005. The decision follows his recent nomination as Executive Vice President of the International Finance Corporation (IFC) and member of the Group Management of the World Bank.

On behalf of the Company, Mr. Loudon expressed sincere thanks and gratitude for the valuable contribution Mr. Thunell has made to Akzo Nobel.

- - -

Note for the editor

Akzo Nobel, based in the Netherlands, serves customers throughout the world with healthcare products, coatings and chemicals. Consolidated revenues for 2004 totaled EUR 12.7 billion. The Company currently employs some 62,000 people in more than 80 countries. The financial results for the third quarter will be published on October 19, 2005.

Internet: www.akzonobel.com

Not for publication - for more information

Akzo Nobel N.V.

Contact: Paul van der Boor, Head Communications Akzo Nobel The Netherlands

Phone: + 31 26 366 37 13

Safe Harbor Statement*

This press release may contain statements which address such key issues as Akzo Nobel's growth strategy, future financial results, market positions, product development, pharmaceutical products in the pipeline, and product approvals. Such statements, including but not limited to the "Outlook", should be carefully considered and it should be understood that many factors could cause forecasted and actual results to differ from these statements. These factors include, but are not limited to, price fluctuations, currency fluctuations, developments in raw material and personnel costs, pensions, physical and environmental risks, legal issues, and legislative, fiscal, and other regulatory measures. These factors also include changes in regulations or interpretations related to the implementation and reporting under IFRS, decisions to apply a different option of presentation permitted by IFRS, and various other factors related to the implementation of IFRS, including the implementation of IAS 32 and 39 for financial instruments. Stated competitive positions are based on management estimates supported by information provided by specialized external agencies. For a more complete discussion of the risk factors affecting our business please refer to our Annual Report on Form 20-F filed with the United States Securities and Exchange Commission, a copy of which can be found on the Company's website www.akzonobel.com.

^{*} Pursuant to the U.S. Private Securities Litigation Reform Act 1995.